
While we become empowered with the technological enablers of centralized and statistical monitoring, it can be challenging to envision the respective functions of DMs and CRAs.

While we become empowered with the technological enablers of centralized and statistical monitoring, it can be challenging to envision the respective functions of DMs and CRAs.


Applied Clinical Trials
OmniComm Systems, a global provider of clinical data management technology, announced survey results from respondents that included 16 sponsor organizations and 13 contract research organizations (CROs).

Applied Clinical Trials
Quintiles announced the addition of advanced statistical monitoring and predictive analytics capabilities to its risk-based monitoring (RBM) solution. Predictive and Advanced Analytics provide model-based capabilities are fully integrated into the solution and are underpinned by Quintiles Infosario® technology platform. These new capabilities are intended to improve precision in risk identification by better understanding underlying “white noise” from safety trigger processes.

Applied Clinical Trials
CluePoints, a provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, introduced software to enable analyses of operational data using a risk-based monitoring approach.

Applied Clinical Trials
With the clinical trial industry’s focus on improving monitoring efficiency and leveraging a variety of risk-based monitoring (RbM) models, novel eClinical technologies are emerging to facilitate clinical trial monitoring productivity.

Applied Clinical Trials
“Never assume that something obvious is true,”

Applied Clinical Trials
Clinical trial patient retention and dropout continues to be an issue amongst biopharmaceutical sponsors, as patient dropouts minimize the statistical power of clinical trial data, requiring study teams to enroll additional patients.

Applied Clinical Trials
Often overlooked in early evaluation of RBM are the tools and technologies required for successful implementation. Without the right tools to track and prioritize the shift from traditional monitoring to RBM, successful implementation is doubtful, posing detrimental consequences not only for the monitors, but also the overall trial.

Applied Clinical Trials
That's because the discussion shifted away from one focused on changing monitoring methods and doing reduced source document verification (SDV) to 'intelligent monitoring.'

Applied Clinical Trials
The concept of risk-based monitoring (RbM) is evolving, as nonprofit organizations continue to collaborate with the biopharmaceutical/medical device industry to investigate, pilot and implement RbM practices.

Applied Clinical Trials
Redefining this paradigm may help dispel current misperceptions around RBM and better deliver on the promise of this growing approach.

Applied Clinical Trials
While capable of conducting high-quality trials, the current oversight process can be expensive and inefficient.

Applied Clinical Trials
Steve Powell, PRA Executive VP Clinical Informatics and Late Phase Services Talks About Risk-Based Monitoring (RBM)

Applied Clinical Trials
True efficiency requires the move to a company-wide ECM solution that supports the entire content lifecycle.